# Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.

> **NCT07653412** · — · RECRUITING · sponsor: **National and Kapodistrian University of Athens** · enrollment: 220 (estimated)

## Conditions studied

- Obesity (Disorder)
- Anti-obesity Agents
- Precision Medicine

## Interventions

- **DRUG:** Semaglutide or Tirzepatide

## Key facts

- **NCT ID:** NCT07653412
- **Lead sponsor:** National and Kapodistrian University of Athens
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-22
- **Primary completion:** 2027-01-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07653412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07653412, "Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07653412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*